Identifying early signs of Alzheimer's disease using advanced imaging and biomarker analysis
Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers
This study is trying to find early signs of Alzheimer's disease in people who are at risk, using advanced brain scans and blood tests to help with earlier diagnosis and treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 50 Years to 79 Years |
| Sex | All |
| Sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Academic / other |
| Locations | 1 site (Nanjing, Jiangsu) |
| Trial ID | NCT06561906 on ClinicalTrials.gov |
What this trial studies
This study aims to develop diagnostic and prognostic models for identifying individuals at high risk of progressing from preclinical stages of Alzheimer's disease to mild cognitive impairment and dementia. By utilizing a combination of demographic, cognitive, behavioral, multimodal MRI, genetic, and plasma biomarker data, the research seeks to uncover the neural mechanisms and biological pathways involved in Alzheimer's progression. Advanced analytical methods will be employed to analyze MRI data and explore the interaction effects of genetic risk factors. The ultimate goal is to enhance early diagnosis and intervention strategies for Alzheimer's disease.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 50-79 with at least 8 years of education who are at risk for cognitive decline.
Not a fit: Patients with a history of neurological disorders or severe mental health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier identification of individuals at risk for Alzheimer's disease, allowing for timely interventions.
How similar studies have performed: Other studies have shown promise in using multimodal imaging and biomarkers for early detection of Alzheimer's disease, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The inclusion criteria were 50-79 years old and having 8 or more years of education. Exclusion Criteria: * Participants with a history of stroke, other neurological disorders that could lead to cognitive impairment (Parkinson's disease, encephalitis, epilepsy, brain tumors, etc.), severe anxiety or depression, and contraindications for magnetic resonance imaging (MRI) were not enrolled.
Where this trial is running
Nanjing, Jiangsu
- Nanjing Drum Tower Hospital — Nanjing, Jiangsu, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.